390
Participants
Start Date
July 9, 2024
Primary Completion Date
July 31, 2028
Study Completion Date
December 31, 2028
GFH375
GFH375 will be administered at the assigned dose level, orally, until disease progression or intolerable toxicity.
RECRUITING
Shanghai Chest Hospital, Shanhai
NOT_YET_RECRUITING
The First Affiliated Hospital of Anhui Medical University, Hefei
RECRUITING
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing
RECRUITING
Peking Union Medical College Hospital, Beijing
RECRUITING
Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou
RECRUITING
The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou
NOT_YET_RECRUITING
Guangxi Medical University Cancer Hospital, Nanning
NOT_YET_RECRUITING
Harbin Medical University Cancer Hospital, Haerbin
RECRUITING
The First Affiliated Hospital of Zhengzhou University, Zhengzhou
RECRUITING
Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan
RECRUITING
Hunan Cancer Hospital, Changsha
RECRUITING
Jiangsu Province Hospital, Nanjing
NOT_YET_RECRUITING
Liaoning Cancer Hospital & Institute, Shenyang
RECRUITING
The First Affiliated Hospital of China Medical University, Shenyang
RECRUITING
Shandong Cancer Hospital, Jinan
NOT_YET_RECRUITING
Sichuan Cancer Hospital, Chengdu
NOT_YET_RECRUITING
Tianjin Medical University Cancer Institute & Hospital, Tianjing
NOT_YET_RECRUITING
The First Affiliated Hospital Zhejiang University School of Medicine, Hangzhou
RECRUITING
The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou
RECRUITING
Zhejiang Cancer Hospital, Hangzhou
Genfleet Therapeutics (Shanghai) Inc.
INDUSTRY